{"entity":{"id":"trucheck-intelli","kind":"drug","name":"Trucheck Intelli","aka":["TruCheck","Trucheck"],"tldr":"Datar Cancer Genetics' blood test that looks for clumps of tumour cells, sold privately in the UK; the developer's marketing figures go beyond what its own papers report.","summary":"Datar Cancer Genetics runs the test in laboratories in Nashik, India, and Guildford, UK. In the company-authored Gaya et al. (Cancer Cytopathology 2021), C-ETACs were found in 91.8% of 9,416 people with known cancer and 92.6% of 6,025 symptomatic people diagnosed with cancer, and were undetectable in 96.3% of 13,919 asymptomatic people, meaning about 3.7% tested positive; staining matched histology in 93.1% of a subset. Akolkar et al. (International Journal of Cancer 2020) reported detection in 89.8% of 5,509 cancers and in 3% of 8,493 people with no abnormal findings.\n\nDatar's 2022 Trucheck Intelli brochure claims detection of over 70 solid cancer types, detection of the cancers it screens for 95% of the time, and false positives in around 1% of cases, citing Gaya 2021; that paper's abstract reports neither the 95% nor the 1% figure. No stage I sensitivity has been published, and no peer-reviewed screening-population positive predictive value. A UK reseller lists it at £1,105 plus an £89 GP consultation (Midland Health); that is a reseller's price. CE marking is stated by resellers but was not confirmed from a primary source, and no MHRA, CDSCO or FDA status was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Gaya et al., Cancer Cytopathology 2021","url":"https://doi.org/10.1002/cncy.22366"},{"label":"Akolkar et al., International Journal of Cancer 2020","url":"https://doi.org/10.1002/ijc.32815"},{"label":"Trucheck Intelli brochure (2022)","url":"https://midlandhealth.co.uk/wp-content/uploads/2023/01/Trucheck-Intelli.pdf"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","ctc-capture"],"targets":[],"drugs":[],"companies":["datar-cancer-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-trucheck-c-etac-cancer-cytopathol-2021"],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","Marketing claims (95% detection, 1% false positives) are not in the cited paper's abstract, which gives a positive rate of about 3.7% in people without symptoms.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"Trucheck","modality":"Multi-cancer blood test (circulating tumour cell clusters, immunocytochemistry)","mechanism":"Harvests circulating ensembles of tumour-associated cells (C-ETACs) from blood and profiles them with organ-specific antibody stains to suggest an organ of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[{"country":"UK","listPrice":"£1,105 plus £89 GP consultation (reseller Midland Health, not Datar)","source":"https://midlandhealth.co.uk/tests-and-diagnostics/trucheck-intelli/","asOf":"2026-10-29"}],"regulatoryEvents":[]},"route":"/drugs/trucheck-intelli/","neighbours":{"technology":[{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"datar-cancer-genetics","kind":"company","name":"Datar Cancer Genetics","route":"/companies/datar-cancer-genetics/"}],"paper":[{"id":"paper-trucheck-c-etac-cancer-cytopathol-2021","kind":"paper","name":"Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging","route":"/key-papers/paper-trucheck-c-etac-cancer-cytopathol-2021/"}]}}